entertainment -WSS

entertainment

author：entertainment 2025-09-30 00:10:01 - browse：57559

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.

For more on what we cover, here’s more on Amylyx; here’s the story on hemophilia gene therapy; here’s the news on Madrigal Pharmaceuticals’ drug for MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medicare Advantage proposed rates disappoint insurers

focus

WSS

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Senators start work on Medicare physician payment reform

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Why Novartis is going to walk from its acquisition of MorphoSys

What’s missing from the debate over nursing home staff minimums

hotspot

entertainment

hotspot

Drug repurposing or repositioning? The language matters

Medicare Advantage proposed rates disappoint insurers

Medicare proposal to cover medical devices draws a mixed reaction

Readout LOUD: Venture capital, Gilead, and more M&A

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The dental labor crisis is a moment of opportunity

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The Readout: Gilead, Bernie Sanders, and other pharma news

Novavax promises a turnaround & Lilly roils the obesity market

The Readout: Gilead, Bernie Sanders, and other pharma news

hotspot

PhRMA lawsuit over Medicare drug price negotiation tossed

The CDC's new social media misinformation war

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Medicare Advantage proposed rates disappoint insurers

Medicare threatens to cut off funding for HCA's Mission hospital

Why Novartis is going to walk from its acquisition of MorphoSys

knowledge

focus

explore

focus